Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
...reatmen...
...eral Recommendations for G1–G3 GEP-NE...
...tion 1.1Selection of initial treatment opt...
...tion 1.2All treatment decisions should be g...
...endation 1.3Patients should be assess...
...mic Therapy for Metastatic G1–G2 Gas...
...stemic Therapy for G1–G2 GI-NETs...
...2.1SSAs (octreotide or lanreotide) are recom...
...2.2In the less common circumstance of patient...
...or Later-line Systemic Therapy for G1â...
...dation 2.3Peptide receptor radionu...
....4Everolimus is recommended for patients with non-...
...herapy for Metastatic G1–G2 Pancreati...
...t-line Systemic Therapy for G1–G2 panNETs
...mmendation 3.1SSAs (octreotide or lanreotide) a...
...commendation 3.2Chemotherapy (e.g....
...ion 3.3Chemotherapy (e.g., CAPTEM), everolimu...
...econd- or Later-line Systemic Therapy for...
....4PRRT for SSTR-positive tumors, che...
...temic Therapy for G3 GEP-NETs...
...ecommendation 4.1The range of systemic options o...
Table 1. WHO Classification and Gradi...
...gure 1. Systemic Therapy for Tumor C...
...s that cancer clinical trials are vital to inform...